新華製藥(000756.SZ):控股股東已增持120萬股H股 擬繼續增持公司H股
格隆匯 6 月 30日丨新華製藥(000756.SZ)公佈,公司於2020年6月30日接到維斌有限公司(WELL BRING LTD.,香港)通知,其通過香港聯合交易所有限公司交易系統增持了新華製藥部分H股120萬股,約佔新華製藥已發行H股的0.62%,約佔新華製藥已發行總股份的0.19%。
華魯控股及其附屬公司計劃在未來6個月內(自本次增持之日起算)繼續增持新華製藥H股股份,每12個月增持不超過新華製藥已發行總股份2%(包括上述H股增持)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.